NCT05104125 - Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

January 12, 2022

Primary Completion Date

April 10, 2023

Study Completion Date

April 10, 2023

Conditions

Acne Vulgaris

Interventions

DRUG

ASC40 25mg

25mg of ASC40 orally once daily for 12 weeks.

DRUG

ASC40 50mg

50mg of ASC40 orally once daily for 12 weeks.

DRUG

ASC40 75mg

75mg of ASC40 orally once daily for 12 weeks.

DRUG

Placebo

Placebo orally once daily for 12 weeks.

Trial Locations (1)

Huashan Hospital Fudan University, Shanghai